Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

Authors :: Andrew Blauvelt
Mark Lebwohl
Richard G. Langley
Katelyn Rowland
Ya-Wen Yang
Daphne Chan
Megan Miller
Yin You
Jenny Yu
Diamant Thaҫi
Peter Foley
Kim A. Papp
Source :: Journal of the American Academy of Dermatology.
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.

Tools